KR20120104196A - Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커 - Google Patents

Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커 Download PDF

Info

Publication number
KR20120104196A
KR20120104196A KR1020127011401A KR20127011401A KR20120104196A KR 20120104196 A KR20120104196 A KR 20120104196A KR 1020127011401 A KR1020127011401 A KR 1020127011401A KR 20127011401 A KR20127011401 A KR 20127011401A KR 20120104196 A KR20120104196 A KR 20120104196A
Authority
KR
South Korea
Prior art keywords
level
subject
polypeptide
akt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127011401A
Other languages
English (en)
Korean (ko)
Inventor
데니스 드라이진
션 오'브라이언
케나 안데레스
다니엘 디. 본호프
존 케이. 씨. 림
클레어 에스. 파제트
조슈아 알. 블리에사트
캐롤린 비. 호
윌리엄 쥐. 라이스
애덤 시디퀴-제인
Original Assignee
사일린 파마슈티칼스, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사일린 파마슈티칼스, 인크 filed Critical 사일린 파마슈티칼스, 인크
Publication of KR20120104196A publication Critical patent/KR20120104196A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/575—
    • G01N33/57515—
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020127011401A 2009-10-02 2010-10-04 Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커 Withdrawn KR20120104196A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24827009P 2009-10-02 2009-10-02
US61/248,270 2009-10-02
US25580509P 2009-10-28 2009-10-28
US61/255,805 2009-10-28
US32377110P 2010-04-13 2010-04-13
US61/323,771 2010-04-13
US38068510P 2010-09-07 2010-09-07
US61/380,685 2010-09-07

Publications (1)

Publication Number Publication Date
KR20120104196A true KR20120104196A (ko) 2012-09-20

Family

ID=43128291

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011401A Withdrawn KR20120104196A (ko) 2009-10-02 2010-10-04 Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커

Country Status (11)

Country Link
US (1) US20110212845A1 (enExample)
EP (1) EP2483686A1 (enExample)
JP (1) JP2013506836A (enExample)
KR (1) KR20120104196A (enExample)
AU (1) AU2010300307A1 (enExample)
BR (1) BR112012007555B1 (enExample)
CA (1) CA2776278A1 (enExample)
IL (1) IL218935A0 (enExample)
IN (1) IN2012DN03817A (enExample)
MX (1) MX2012003997A (enExample)
WO (1) WO2011041785A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025121762A1 (ko) * 2023-12-04 2025-06-12 대한민국(질병관리청 국립보건연구원장) 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling
US9146545B2 (en) 2012-11-27 2015-09-29 Honeywell International Inc. Multivariable control system for setpoint design
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
KR101593595B1 (ko) * 2013-10-08 2016-02-12 한국생명공학연구원 Ｃｘ－４９４５를 유효성분으로 함유하는 스플라이싱 조절제
WO2015053452A1 (ko) * 2013-10-08 2015-04-16 한국생명공학연구원 Ｃｘ－４９４５를 유효성분으로 함유하는 스플라이싱 조절제
US20170051062A1 (en) * 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
MX375557B (es) * 2014-07-18 2025-03-06 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
WO2016133860A1 (en) * 2015-02-16 2016-08-25 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023190820A1 (ja) * 2022-03-30 2023-10-05 公立大学法人福島県立医科大学 抗ＣＫ２α抗体又はその断片
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200715636A (en) 2005-10-04 2007-04-16 Antig Tech Co Ltd Method of controlling fuel concentration used in direct liquid fuel cell
ES2528316T3 (es) 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
US8488289B2 (en) 2006-09-27 2013-07-16 International Rectifier Corporation Current protection circuit for intelligent power switch
US20090035609A1 (en) 2007-07-31 2009-02-05 Apple Inc. Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025121762A1 (ko) * 2023-12-04 2025-06-12 대한민국(질병관리청 국립보건연구원장) 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
IN2012DN03817A (enExample) 2015-08-28
JP2013506836A (ja) 2013-02-28
BR112012007555B1 (pt) 2020-09-29
IL218935A0 (en) 2012-07-31
US20110212845A1 (en) 2011-09-01
WO2011041785A1 (en) 2011-04-07
BR112012007555A2 (pt) 2016-10-25
CA2776278A1 (en) 2011-04-07
MX2012003997A (es) 2012-07-25
EP2483686A1 (en) 2012-08-08
AU2010300307A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
KR20120104196A (ko) Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커
US20240325398A1 (en) Combination therapies
TWI877297B (zh) 化合物及其用途
US20110065712A1 (en) Tricyclic compounds and pharmaceutical uses thereof
US20120129849A1 (en) Deuterated serine-threonine protein kinase modulators
AU2010295619A1 (en) Novel tricyclic protein kinase modulators
EP2656077A1 (en) Drug selection for malignant cancer therapy using antibody-based arrays
CA2828052A1 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
WO2023009834A2 (en) Methods of treating cancer
WO2012170827A2 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JP2012533624A (ja) Ｃｋ２モジュレーターを用いた併用療法
EP3314265B1 (en) Methods of treatment with taselisib
KR20250048049A (ko) 암의 치료에 사용하기 위한 mta-협동적 prmt5 억제제
CN118043053A (zh) 治疗癌症的方法
EP4188447A1 (en) Compounds and uses thereof
US9903867B2 (en) Methods for predicting and improving the survival of colorectal cancer patients
WO2026015745A1 (en) Macrocyclic ras inhibitors
EA047751B1 (ru) Соединения и способы их применения
HK1263276A1 (en) Method for selecting a therapy for the treatment of colorectal cancer patients
NZ734946A (en) Combination treatment protocol
HK1223156B (en) Methods for predicting and improving the survival of colorectal cancer patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000